FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:961-966 March 29, 2001 Number 13 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Depression commonly complicates treatment with the cytokine interferon alfa-2b. Laboratory animals pretreated with antidepressants have less severe depression-like symptoms after the administration of a cytokine. We sought to determine whether a similar strategy would be effective in humans.

Methods In a double-blind study of 40 patients with malignant melanoma who were eligible for high-dose interferon alfa therapy, we randomly assigned 20 patients to receive the antidepressant paroxetine and 20 to receive placebo. The treatment was begun 2 weeks before the initiation of interferon alfa and continued for the first 12 weeks of interferon alfa therapy.

Results During the first 12 weeks of interferon alfa therapy, symptoms consistent with a diagnosis of major depression developed in 2 of 18 patients in the paroxetine group (11 percent) and 9 of 20 patients in the placebo group (45 percent) (relative risk, 0.24; 95 percent confidence interval, 0.08 to 0.93). Severe depression necessitated the discontinuation of interferon alfa before 12 weeks in 1 of the 20 patients in the paroxetine group (5 percent), as compared with 7 patients in the placebo group (35 percent) (relative risk, 0.14; 95 percent confidence interval, 0.05 to 0.85). The incidence of adverse events was similar in the two groups.

Conclusions In patients with malignant melanoma, pretreatment with paroxetine appears to be an effective strategy for minimizing depression induced by interferon alfa.

Source Information

From the Department of Psychiatry and Behavioral Sciences (D.L.M., J.F.G., S.P., R.S.G., C.B.N., A.H.M.) and the Winship Cancer Institute (D.H.L, K.G.), Emory University School of Medicine; and the Department of Biostatistics, Rollins School of Public Health, Emory University (A.K.M.) — both in Atlanta.

Address reprint requests to Dr. Miller at the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1639 Pierce Dr., Suite 4000, Atlanta, GA 30322, or at amill02{at}emory.edu.

Full Text of this Article

Related Letters:

Interferon Alfa–Induced Adverse Effects in Patients with a Psychiatric Diagnosis
Pariante C. M., Landau S., Carpiniello B., the Cagliari Group
Extract | Full Text | PDF  
N Engl J Med 2002; 347:148-149, Jul 11, 2002. Correspondence

This article has been cited by other articles:

• Schaefer, M., Winterer, J., Sarkar, R., Uebelhack, R., Franke, L., Heinz, A., Friebe, A. (2008). Three Cases of Successful Tryptophan Add-On or Monotherapy of Hepatitis C and IFN{alpha}-Associated Mood Disorders. Psychosomatics 49: 442-446 [Abstract] [Full Text]  
• Tsao, C-W., Lin, Y-S., Cheng, J-T., Lin, C-F., Wu, H-T., Wu, S-R., Tsai, W-H. (2008). Interferon-{alpha}-induced serotonin uptake in Jurkat T cells via mitogen-activated protein kinase and transcriptional regulation of the serotonin transporter. J Psychopharmacol 22: 753-760 [Abstract]  
• Levy, M. R. (2008). Cancer Fatigue: A Neurobiological Review for Psychiatrists. Psychosomatics 49: 283-291 [Abstract] [Full Text]  
• Spiegel, D. (2008). Losing Sleep Over Cancer. JCO 26: 2431-2432 [Full Text]  
• Lydiatt, W. M., Denman, D., McNeilly, D. P., Puumula, S. E., Burke, W. J. (2008). A Randomized, Placebo-Controlled Trial of Citalopram for the Prevention of Major Depression During Treatment for Head and Neck Cancer. Arch Otolaryngol Head Neck Surg 134: 528-535 [Abstract] [Full Text]  
• Kraus, M R, Schafer, A, Schottker, K, Keicher, C, Weissbrich, B, Hofbauer, I, Scheurlen, M (2008). Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 57: 531-536 [Abstract] [Full Text]  
• Bannink, M., Kruit, W. H.J., Van Gool, A. R., Sleijfer, S., van der Holt, B., Eggermont, A. M.M., Stoter, G., Hengeveld, M. W. (2008). Interferon-{alpha} in Oncology Patients: Fewer Psychiatric Side Effects Than Anticipated. Psychosomatics 49: 56-63 [Abstract] [Full Text]  
• Miller, A. H., Raison, C. L. (2008). Immune System Contributions to the Pathophysiology of Depression. Focus 6: 36-45 [Abstract] [Full Text]  
• Murray, K. F., Rodrigue, J. R., Gonzalez-Peralta, R. P., Shepherd, J., Barton, B. A., Robuck, P. R., Schwarz, K. B., for the PEDS-C Clinical Research Network, (2007). Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection. Clin Trials 4: 661-673 [Abstract]  
• Myint, A.M., O'Mahony, S., Kubera, M., Kim, Y.K., Kenny, C., Kaim-Basta, A., Steinbusch, H.W.M., Leonard, B.E. (2007). Role of paroxetine in interferon-{alpha}-induced immune and behavioural changes in male Wistar rats. J Psychopharmacol 21: 843-850 [Abstract]  
• Jackson, C. W., Jackson, K. H. (2007). Comorbid Depression in Adult Oncology. Journal of Pharmacy Practice 20: 360-367 [Abstract]  
• Reynolds, C. F. III, Dew, M. A., Lenze, E. J., Whyte, E. M. (2007). Preventing Depression in Medical Illness: A New Lead?. Arch Gen Psychiatry 64: 884-885 [Full Text]  
• Irwin, M. R. (2007). Depression and Risk of Cancer Progression: An Elusive Link. JCO 25: 2343-2344 [Full Text]  
• Malek-Ahmadi, P., Prabhu, F. (2006). Venlafaxine for Treatment of Interferon Alfa-Induced Depression. The Annals of Pharmacotherapy 40: 2075-2075 [Full Text]  
• Weinert, C., Meller, W. (2006). Epidemiology of Depression and Antidepressant Therapy After Acute Respiratory Failure. Psychosomatics 47: 399-407 [Abstract] [Full Text]  
• Manns, M P, Wedemeyer, H, Cornberg, M (2006). Treating viral hepatitis C: efficacy, side effects, and complications.. Gut 55: 1350-1359 [Full Text]  
• Camacho, A., Ng, B. (2006). Methylphenidate for {alpha}-interferon induced depression. J Psychopharmacol 20: 687-689 [Abstract]  
• Pao, M., Ballard, E. D., Rosenstein, D. L., Wiener, L., Wayne, A. S. (2006). Psychotropic Medication Use in Pediatric Patients With Cancer. Arch Pediatr Adolesc Med 160: 818-822 [Abstract] [Full Text]  
• Pariante, C. M. (2006). The glucocorticoid receptor: part of the solution or part of the problem?. J Psychopharmacol 20: 79-84 [Abstract]  
• Crone, C. C., Gabriel, G. M., DiMartini, A. (2006). An Overview of Psychiatric Issues in Liver Disease for the Consultation-Liaison Psychiatrist. Psychosomatics 47: 188-205 [Abstract] [Full Text]  
• Mistler, L. A., Brunette, M. F., Marsh, B. J., Vidaver, R. M., Luckoor, R., Rosenberg, S. D. (2006). Hepatitis C treatment for people with severe mental illness.. Psychosomatics 47: 93-107 [Abstract] [Full Text]  
• Hurley, K. E., Chapman, P. B. (2005). Helping Melanoma Patients Decide Whether to Choose Adjuvant High-Dose Interferon-{alpha}2b. The Oncologist 10: 739-742 [Abstract] [Full Text]  
• Goldman Consensus Group, (2005). The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 11: 328-337 [Abstract]  
• Kop, W. J., Gottdiener, J. S. (2005). The Role of Immune System Parameters in the Relationship Between Depression and Coronary Artery Disease. Psychosom. Med. 67: S37-S41 [Abstract] [Full Text]  
• Rifai, M. A., Rosenstein, D. L. (2005). Hepatitis C and Psychiatry. Focus 3: 194-202 [Abstract] [Full Text]  
• Kornfeld, D. S., Wharton, R. N. (2005). The American Psychiatric Publishing Textbook of Psychosomatic Medicine. Psychosomatics 46: 95-103 [Full Text]  
• Friedberg, J. W., Kim, H., McCauley, M., Hessel, E. M., Sims, P., Fisher, D. C., Nadler, L. M., Coffman, R. L., Freedman, A. S. (2005). Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-{alpha}/{beta}-inducible gene expression, without significant toxicity. Blood 105: 489-495 [Abstract] [Full Text]  
• Kalyoncu, O. A., Tan, D., Mirsal, H., Pektas, O., Beyazyurek, M. (2005). Major depressive disorder with psychotic features induced by interferon-{alpha} treatment for hepatitis C in a polydrug abuser. J Psychopharmacol 19: 102-105 [Abstract]  
• Manns, M. P., Wedemeyer, H. (2004). Treatment of Hepatitis C in HIV-Infected Patients: Significant Progress But Not the Final Step. JAMA 292: 2909-2913 [Full Text]  
• Tsao, H., Atkins, M. B., Sober, A. J. (2004). Management of Cutaneous Melanoma. NEJM 351: 998-1012 [Full Text]  
• Matthews, S. C., Paulus, M. P., Dimsdale, J. E. (2004). Contribution of Functional Neuroimaging to Understanding Neuropsychiatric Side Effects of Interferon in Hepatitis C. Psychosomatics 45: 281-286 [Abstract] [Full Text]  
• Lebowitz, B. D. (2004). Clinical Trials in Late Life: New Science in Old Paradigms. Gerontologist 44: 452-458 [Abstract] [Full Text]  
• Pirl, W. F. (2004). Evidence Report on the Occurrence, Assessment, and Treatment of Depression in Cancer Patients. J Natl Cancer Inst Monogr 2004: 32-39 [Abstract] [Full Text]  
• Fisch, M. (2004). Treatment of Depression in Cancer. J Natl Cancer Inst Monogr 2004: 105-111 [Abstract] [Full Text]  
• Greenberg, D. B. (2004). Barriers to the Treatment of Depression in Cancer Patients. J Natl Cancer Inst Monogr 2004: 127-135 [Abstract] [Full Text]  
• Onyike, C. U., Bonner, J. O., Lyketsos, C. G., Treisman, G. J. (2004). Mania During Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin. Am. J. Psychiatry 161: 429-435 [Full Text]  
• Maddock, C., Baita, A., Orru, M. G., Sitzia, R., Costa, A., Muntoni, E., Farci, M. G., Carpiniello, B., Pariante, C. M. (2004). Psychopharmacological Treatment of Depression, Anxiety, Irritability and Insomnia in Patients Receiving Interferon-{alpha}: a Prospective Case Series and a Discussion of Biological Mechanisms. J Psychopharmacol 18: 41-46 [Abstract]  
• Gochee, P. A., Powell, E. E., Purdie, D. M., Pandeya, N., Kelemen, L., Shorthouse, C., Jonsson, J. R., Kelly, B. (2004). Association Between Apolipoprotein E {epsilon}4 and Neuropsychiatric Symptoms During Interferon {alpha} Treatment for Chronic Hepatitis C. Psychosomatics 45: 49-57 [Abstract] [Full Text]  
• Alliot, C. (2004). Fluoxetine Versus Placebo in Advanced Cancer Outpatients. JCO 22: 204-205 [Full Text]  
• Loftis, J. M., Hauser, P. (2003). Safety of the Treatment of Interferon-Alpha-Induced Depression. Psychosomatics 44: 524-526 [Full Text]  
• Hoffman, R. G., Cohen, M. A., Alfonso, C. A., Weiss, J. J., Jones, S., Keller, M., Condemarin, J. R., Chiu, N.-M., Jacobson, J. M. (2003). Treatment of Interferon-Induced Psychosis in Patients With Comorbid Hepatitis C and HIV. Psychosomatics 44: 417-420 [Full Text]  
• Russo, S., Kema, I. P., Fokkema, M. R., Boon, J. C., Willemse, P. H. B., de Vries, E. G. E., den Boer, J. A., Korf, J. (2003). Tryptophan as a Link between Psychopathology and Somatic States. Psychosom. Med. 65: 665-671 [Abstract] [Full Text]  
• Fisch, M. J., Loehrer, P. J., Kristeller, J., Passik, S., Jung, S.-H., Shen, J., Arquette, M. A., Brames, M. J., Einhorn, L. H. (2003). Fluoxetine Versus Placebo in Advanced Cancer Outpatients: A Double-Blinded Trial of the Hoosier Oncology Group. JCO 21: 1937-1943 [Abstract] [Full Text]  
• Kefford, R. F. (2003). Adjuvant therapy of cutaneous melanoma: the interferon debate. Ann Oncol 14: 358-365 [Abstract] [Full Text]  
• Pasic, J., Levy, W. C., Sullivan, M. D. (2003). Cytokines in Depression and Heart Failure. Psychosom. Med. 65: 181-193 [Abstract] [Full Text]  
• Kornfeld, D. S. (2002). Consultation-Liaison Psychiatry: Contributions to Medical Practice. Am. J. Psychiatry 159: 1964-1972 [Abstract] [Full Text]  
• Schneider, R. K., Levenson, J. L. (2002). Update in Psychiatry. ANN INTERN MED 137: 671-677 [Full Text]  
• Kirkwood, J. M., Bender, C., Agarwala, S., Tarhini, A., Shipe-Spotloe, J., Smelko, B., Donnelly, S., Stover, L. (2002). Mechanisms and Management of Toxicities Associated With High-Dose Interferon Alfa-2b Therapy. JCO 20: 3703-3718 [Abstract] [Full Text]  
• Pariante, C. M., Landau, S., Carpiniello, B., the Cagliari Group, (2002). Interferon Alfa-Induced Adverse Effects in Patients with a Psychiatric Diagnosis. NEJM 347: 148-149 [Full Text]  
• Okereke, O. I. (2002). Neuropsychiatric Complications Associated With Interferon-Alpha-2b Treatment of Malignant Melanoma. Psychosomatics 43: 237-240 [Full Text]  
• (2001). Psychiatric Aspects of HIV Care. AIDS Clin Care 2001: 6-6 [Full Text]  
• Kraus, M. R., Schafer, A., Scheurlen, M., Miller, A. H., Musselman, D. L., Nemeroff, C. B. (2001). Paroxetine for the Prevention of Depression Induced by Interferon Alfa. NEJM 345: 375-376 [Full Text]  
• (2001). An Antidepressant Prevents Medication-Induced Depression. JWatch Psychiatry 2001: 2-2 [Full Text]  
• (2001). Antidepressant Therapy to Prevent Interferon-Induced Depression. JWatch General 2001: 3-3 [Full Text]